Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoPEHP: Neoadjuvant Palbociclib, Exemestane, Trastuzumab, and Pyrotinib in Breast Cancer
NCT04858516Phase 2Unknown
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of pyrotinib, palbociclib in breast cancer, sponsored by Guangdong Provincial People's Hospital. Status: unknown.
02
Drugs
pyrotinibpalbociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04858516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04858516.